Functional Epstein-Barr virus reservoir in plasma cells derived from infected peripheral blood memory B cells

Blood ◽  
2009 ◽  
Vol 113 (3) ◽  
pp. 604-611 ◽  
Author(s):  
Yassine Al Tabaa ◽  
Edouard Tuaillon ◽  
Karine Bollore ◽  
Vincent Foulongne ◽  
Gael Petitjean ◽  
...  
Keyword(s):  
B Lymphocytes ◽  
Epstein Barr Virus ◽  
Plasma Cells ◽  
Lytic Cycle ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Immediate Early Antigen ◽  
Culture Supernatants ◽  
Healthy Carriers

AbstractThe Epstein-Barr virus (EBV) causes infectious mononucleosis, establishes latency in resting memory B lymphocytes, and is involved in oncogenesis through poorly understood mechanisms. The EBV lytic cycle is initiated during plasma cell differentiation by mRNAs transcripts encoded by BZLF1, which induce the synthesis of EBV proteins such as the immediate-early antigen ZEBRA and the late membrane antigen gp350. Therefore, we assessed the capacity of circulating EBV-infected B lymphocytes from healthy EBV-seropositive subjects to enter and complete the EBV lytic cycle. Purified B lymphocytes were polyclonally stimulated and BZLF1- or gp350-secreting cells (BZLF1-SCs or gp350-SCs) were enumerated by ELISpot assays. The number of BZLF1-SCs ranged from 50 to 480/107 lymphocytes (median, 80; 25th-75th percentiles, 70-150) and gp350-SCs from 10 to 40/107 lymphocytes (median, 17; 25th-75th percentiles, 10-20). gp350-SCs represented only 7.7% to 28.6% of BZLF1-SCs (median, 15%; 25th-75th percentiles, 10.5%-20%). This EBV functional reservoir was preferentially restricted to plasma cells derived from CD27+ IgD− memory B lymphocytes. In 9 of 13 subjects, EBV DNA quantification in B-cell culture supernatants gave evidence of completion of EBV lytic cycle. These results demonstrate that EBV proteins can be secreted by EBV-infected B lymphocytes from healthy carriers, a majority generating an abortive EBV lytic cycle and a minority completing the cycle.

scholarly journals Epstein-Barr virus transformed B lymphocytes produce interleukin-5

Blood ◽  
1990 ◽  
Vol 75 (7) ◽  
pp. 1400-1403 ◽  
Author(s):  
CC Paul ◽  
JR Keller ◽  
JM Armpriester ◽  
MA Baumann
Keyword(s):  
B Cell ◽  
B Lymphocytes ◽  
Messenger Rna ◽  
Epstein Barr Virus ◽  
Northern Analysis ◽  
Interleukin 5 ◽  
Barr Virus ◽  
Epstein Barr ◽  
Semi Solid ◽  
Culture Supernatants

Abstract Interleukin-5 (IL-5) has previously been isolated only as a product of T lymphocytes. We have found that Epstein-Barr virus transformed B lymphocytes produce large amounts of IL-5 activity in culture supernatants, inducing proliferation of murine BCL1 cells, and supporting the selective growth of eosinophil colonies in semi-solid culture. Production of IL-5 messenger RNA by transformed B-cell lines was verified by Northern analysis using a 3.2-kilobase cloned DNA fragment containing the full-length human IL-5 gene, and immunoreactive IL-5 was detected in B-cell culture supernatants. These findings suggest a possible expanded role for the B cell in the induction of eosinophilia, and should serve as a focus for additional investigation into possible roles for IL-5 in human B-cell proliferation and differentiation.

scholarly journals Identification and Characterization of the Physiological Gene Targets of the Essential Lytic Replicative Epstein-Barr Virus SM Protein

2015 ◽  
Vol 90 (3) ◽  
pp. 1206-1221 ◽  
Author(s):  
Jacob Thompson ◽  
Dinesh Verma ◽  
DaJiang Li ◽  
Tim Mosbruger ◽  
Sankar Swaminathan
Keyword(s):  
Dna Replication ◽  
Mechanism Of Action ◽  
Epstein Barr Virus ◽  
Rna Binding ◽  
Lytic Cycle ◽  
Barr Virus ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Sm Protein ◽  
Target Rna

ABSTRACTEpstein-Barr virus (EBV) SM protein is an essential lytic cycle protein with multiple posttranscriptional mechanisms of action. SM binds RNA and increases accumulation of specific EBV transcripts. Previous studies using microarrays and PCR have shown that SM-null mutants fail to accumulate several lytic cycle mRNAs and proteins at wild-type levels. However, the complete effect of SM on the EBV transcriptome has been incompletely characterized. Here we precisely identify the effects of SM on all EBV transcripts by high-throughput RNA sequencing, quantitative PCR (qPCR), and Northern blotting. The effect of SM on EBV mRNAs was highly skewed and was most evident on 13 late genes, demonstrating why SM is essential for infectious EBV production. EBV DNA replication was also partially impaired in SM mutants, suggesting additional roles for SM in EBV DNA replication. While it has been suggested that SM specificity is based on recognition of either RNA sequence motifs or other sequence properties, no such unifying property of SM-responsive targets was discernible. The binding affinity of mRNAs for SM also did not correlate with SM responsiveness. These data suggest that while target RNA binding by SM may be required for its effect, specific activation by SM is due to differences in inherent properties of individual transcripts. We therefore propose a new model for the mechanism of action and specificity of SM and its homologs in other herpesviruses: that they bind many RNAs but only enhance accumulation of those that are intrinsically unstable and poorly expressed.IMPORTANCEThis study examines the mechanism of action of EBV SM protein, which is essential for EBV replication and infectious virus production. Since SM protein is not similar to any cellular protein and has homologs in all other human herpesviruses, it has potential importance as a therapeutic target. Here we establish which EBV RNAs are most highly upregulated by SM, allowing us to understand why it is essential for EBV replication. By comparing and characterizing these RNA transcripts, we conclude that the mechanism of specific activity is unlikely to be based simply on preferential recognition of a target motif. Rather, SM binding to its target RNA may be necessary but not sufficient for enhancing accumulation of the RNA. Preferential effects of SM on its most responsive RNA targets may depend on other inherent characteristics of these specific mRNAs that require SM for efficient expression, such as RNA stability.

scholarly journals Cellular STAT3 Functions via PCBP2 To Restrain Epstein-Barr Virus Lytic Activation in B Lymphocytes

2015 ◽  
Vol 89 (9) ◽  
pp. 5002-5011 ◽  
Author(s):  
Siva Koganti ◽  
Carissa Clark ◽  
Jizu Zhi ◽  
Xiaofan Li ◽  
Emily I. Chen ◽  
...  
Keyword(s):  
Tumor Cells ◽  
B Lymphocytes ◽  
Epstein Barr Virus ◽  
Lytic Cycle ◽  
Substantial Fraction ◽  
Data Set ◽  
Oncolytic Therapy ◽  
Barr Virus ◽  
Infected Cells ◽  
Epstein Barr

ABSTRACTA major hurdle to killing Epstein-Barr virus (EBV)-infected tumor cells using oncolytic therapy is the presence of a substantial fraction of EBV-infected cells that does not support the lytic phase of EBV despite exposure to lytic cycle-promoting agents. To determine the mechanism(s) underlying this refractory state, we developed a strategy to separate lytic from refractory EBV-positive (EBV+) cells. By examining the cellular transcriptome in separated cells, we previously discovered that high levels of host STAT3 (signal transducer and activator of transcription 3) curtail the susceptibility of latently infected cells to lytic cycle activation signals. The goals of the present study were 2-fold: (i) to determine the mechanism of STAT3-mediated resistance to lytic activation and (ii) to exploit our findings to enhance susceptibility to lytic activation. We therefore analyzed our microarray data set, cellular proteomes of separated lytic and refractory cells, and a publically available STAT3 chromatin immunoprecipitation sequencing (ChIP-Seq) data set to identify cellular PCBP2 [poly(C)-binding protein 2], an RNA-binding protein, as a transcriptional target of STAT3 in refractory cells. Using Burkitt lymphoma cells and EBV+cell lines from patients with hypomorphicSTAT3mutations, we demonstrate that single cells expressing high levels of PCBP2 are refractory to spontaneous and induced EBV lytic activation, STAT3 functions via cellular PCBP2 to regulate lytic susceptibility, and suppression of PCBP2 levels is sufficient to increase the number of EBV lytic cells. We expect that these findings and the genome-wide resources that they provide will accelerate our understanding of a longstanding mystery in EBV biology and guide efforts to improve oncolytic therapy for EBV-associated cancers.IMPORTANCEMost humans are infected with Epstein-Barr virus (EBV), a cancer-causing virus. While EBV generally persists silently in B lymphocytes, periodic lytic (re)activation of latent virus is central to its life cycle and to most EBV-related diseases. However, a substantial fraction of EBV-infected B cells and tumor cells in a population is refractory to lytic activation. This resistance to lytic activation directly and profoundly impacts viral persistence and the effectiveness of oncolytic therapy for EBV+cancers. To identify the mechanisms that underlie susceptibility to EBV lytic activation, we used host gene and protein expression profiling of separated lytic and refractory cells. We find that STAT3, a transcription factor overactive in many cancers, regulates PCBP2, a protein important in RNA biogenesis, to regulate susceptibility to lytic cycle activation signals. These findings advance our understanding of EBV persistence and provide important leads on devising methods to improve viral oncolytic therapies.

scholarly journals Hyperphosphorylation of EBNA2 by Epstein-Barr Virus Protein Kinase Suppresses Transactivation of the LMP1 Promoter

2005 ◽  
Vol 79 (9) ◽  
pp. 5880-5885 ◽  
Author(s):  
Wei Yue ◽  
Edward Gershburg ◽  
Joseph S. Pagano
Keyword(s):  
Protein Kinase ◽  
B Lymphocytes ◽  
Epstein Barr Virus ◽  
Lytic Cycle ◽  
Nuclear Antigen ◽  
Virus Protein ◽  
Protein Levels ◽  
Barr Virus ◽  
Latently Infected ◽  
Epstein Barr

ABSTRACT The Epstein-Barr virus (EBV) BGLF4 gene encodes a serine/threonine protein kinase (PK) that is expressed in the cytolytic cycle. EBV nuclear antigen 2 (EBNA2) is a key latency gene essential for immortalization of B lymphocytes and transactivation of viral and cellular promoters. Here we report that EBV PK phosphorylates EBNA2 at Ser-243 and that these two proteins physically associate. PK suppresses EBNA2's ability to transactivate the LMP1 promoter, and Ser-243 of EBNA2 is involved in this suppression. Moreover, EBNA2 is hyperphosphorylated during EBV reactivation in latently infected B cells, which is associated with decreased LMP1 protein levels. This is the first report about the effect of EBV PK on the function of one of its target proteins and regulation of EBNA2 phosphorylation during the EBV lytic cycle.

scholarly journals Terminal Differentiation into Plasma Cells Initiates the Replicative Cycle of Epstein-Barr Virus In Vivo

2005 ◽  
Vol 79 (2) ◽  
pp. 1296-1307 ◽  
Author(s):  
Lauri L. Laichalk ◽  
David A. Thorley-Lawson
Keyword(s):  
Viral Replication ◽  
Epstein Barr Virus ◽  
Plasma Cells ◽  
Acute Stress ◽  
Cytotoxic T Lymphocyte ◽  
Lytic Cycle ◽  
Barr Virus ◽  
Epstein Barr

ABSTRACT In this paper we demonstrate that the cells which initiate replication of Epstein-Barr virus (EBV) in the tonsils of healthy carriers are plasma cells (CD38hi, CD10−, CD19+, CD20lo, surface immunoglobulin negative, and cytoplasmic immunoglobulin positive). We further conclude that differentiation into plasma cells, and not the signals that induce differentiation, initiates viral replication. This was confirmed by in vitro studies showing that the promoter for BZLF1, the gene that begins viral replication, becomes active only after memory cells differentiate into plasma cells and is also active in plasma cell lines. This differs from the reactivation of BZLF1 in vitro, which occurs acutely and is associated with apoptosis and not with differentiation. We suggest that differentiation and acute stress represent two distinct pathways of EBV reactivation in vivo. The fraction of cells replicating the virus decreases as the cells progress through the lytic cycle such that only a tiny fraction actually release infectious virus. This may reflect abortive replication or elimination of cells by the cellular immune response. Consistent with the later conclusion, the cells did not down regulate major histocompatibility complex class I molecules, suggesting that this is not an immune evasion tactic used by EBV and that the cells remain vulnerable to cytotoxic-T-lymphocyte attack.

hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: Implications for EBV-driven lymphomagenesis

2007 ◽  
Vol 121 (3) ◽  
pp. 576-587 ◽  
Author(s):  
Liliana Terrin ◽  
Riccardo Dolcetti ◽  
Irene Corradini ◽  
Stefano Indraccolo ◽  
Jessica Dal Col ◽  
...  
Keyword(s):  
B Lymphocytes ◽  
Epstein Barr Virus ◽  
Lytic Cycle ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals The Epstein-Barr Virus Rta Protein Activates Lytic Cycle Genes and Can Disrupt Latency in B Lymphocytes

1998 ◽  
Vol 72 (10) ◽  
pp. 7978-7984 ◽  
Author(s):  
Tobias Ragoczy ◽  
Lee Heston ◽  
George Miller
Keyword(s):  
Epithelial Cells ◽  
B Lymphocytes ◽  
Epstein Barr Virus ◽  
Lytic Cycle ◽  
Immediate Early ◽  
Late Gene Expression ◽  
Barr Virus ◽  
Viral Genes ◽  
Specific Manner ◽  
Epstein Barr

ABSTRACT The transition of Epstein-Barr virus (EBV) from latency into the lytic cycle is associated with the expression of two immediate-early viral genes, BZLF1 and BRLF1. Overexpression of ZEBRA, the product of BZLF1, is sufficient to disrupt latency in B lymphocytes and epithelial cells by stimulating expression of lytic cycle genes, including BRLF1. The BRLF1 product Rta functions as a transcriptional activator in both B lymphocytes and epithelial cells. However, Rta has recently been reported to disrupt latency in an epithelial specific manner (S. Zalani, E. Holley-Guthrie, and S. Kenney, Proc. Natl. Acad. Sci. USA 93:9194–9199, 1996). Here we demonstrate that expression of Rta is also sufficient for disruption of latency in a permissive B-cell line. In HH514-16 cells, transfection of Rta leads to synthesis of ZEBRA, viral DNA replication, and late gene expression. However, Rta by itself is less potent than ZEBRA in the ability to activate most early and late lytic cycle genes. In light of previous work implicating ZEBRA in the activation of Rta, we suggest a cooperative model for EBV entry into the lytic cycle. Expression of either BZLF1 or BRLF1 triggers expression of the other immediate-early factor, and together these activators act individually or in synergy on downstream targets to activate the viral lytic cycle.

scholarly journals Epstein–Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection

2019 ◽  
Vol 116 (32) ◽  
pp. 16046-16055 ◽  
Author(s):  
Paulina Mrozek-Gorska ◽  
Alexander Buschle ◽  
Dagmar Pich ◽  
Thomas Schwarzmayr ◽  
Ron Fechtner ◽  
...  
Keyword(s):  
B Lymphocytes ◽  
Metabolic Pathways ◽  
Epstein Barr Virus ◽  
Plasma Cells ◽  
Human Tumor ◽  
Proliferating Cells ◽  
Barr Virus ◽  
Epstein Barr

Epstein–Barr virus (EBV) is a human tumor virus and a model of herpesviral latency. The virus efficiently infects resting human B lymphocytes and induces their continuous proliferation in vitro, which mimics certain aspects of EBV’s oncogenic potential in vivo. How lymphoblastoid cell lines (LCLs) evolve from the infected lymphocytes is uncertain. We conducted a systematic time-resolved longitudinal study of cellular functions and transcriptional profiles of newly infected naïve primary B lymphocytes. EBV reprograms the cells comprehensively and globally. Rapid and extensive transcriptional changes occur within 24 h and precede any metabolic and phenotypic changes. Within 72 h, the virus activates the cells, changes their phenotypes with respect to cell size, RNA, and protein content, and induces metabolic pathways to cope with the increased demand for energy, supporting an efficient cell cycle entry on day 3 postinfection. The transcriptional program that EBV initiates consists of 3 waves of clearly discernable clusters of cellular genes that peak on day 2, 3, or 4 and regulate RNA synthesis, metabolic pathways, and cell division, respectively. Upon onset of cell doublings on day 4, the cellular transcriptome appears to be completely reprogrammed to support the proliferating cells, but 3 additional clusters of EBV-regulated genes fine-tune cell signaling, migration, and immune response pathways, eventually. Our study reveals that more than 11,000 genes are regulated upon EBV infection as naïve B cells exit quiescence to enter a germinal center-like differentiation program, which culminates in immortalized, proliferating cells that partially resemble plasmablasts and early plasma cells.

scholarly journals Epstein-Barr virus transformed B lymphocytes produce interleukin-5

Blood ◽  
1990 ◽  
Vol 75 (7) ◽  
pp. 1400-1403
Author(s):  
CC Paul ◽  
JR Keller ◽  
JM Armpriester ◽  
MA Baumann
Keyword(s):  
B Cell ◽  
B Lymphocytes ◽  
Messenger Rna ◽  
Epstein Barr Virus ◽  
Northern Analysis ◽  
Interleukin 5 ◽  
Barr Virus ◽  
Epstein Barr ◽  
Semi Solid ◽  
Culture Supernatants

Interleukin-5 (IL-5) has previously been isolated only as a product of T lymphocytes. We have found that Epstein-Barr virus transformed B lymphocytes produce large amounts of IL-5 activity in culture supernatants, inducing proliferation of murine BCL1 cells, and supporting the selective growth of eosinophil colonies in semi-solid culture. Production of IL-5 messenger RNA by transformed B-cell lines was verified by Northern analysis using a 3.2-kilobase cloned DNA fragment containing the full-length human IL-5 gene, and immunoreactive IL-5 was detected in B-cell culture supernatants. These findings suggest a possible expanded role for the B cell in the induction of eosinophilia, and should serve as a focus for additional investigation into possible roles for IL-5 in human B-cell proliferation and differentiation.

scholarly journals Effects of Epstein-Barr Virus Infection on CD19+ B Lymphocytes in Patients with Immunorelated Pancytopenia

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Yang Zhao ◽  
Yihao Wang ◽  
Hui Liu ◽  
Kai Ding ◽  
Chunyan Liu ◽  
...  
Keyword(s):  
B Cells ◽  
B Lymphocytes ◽  
Epstein Barr Virus ◽  
B Lymphocyte ◽  
Enzyme Linked Immunosorbent Assay ◽  
Epstein Barr Virus Infection ◽  
Barr Virus ◽  
Ebv Infection ◽  
Ebv Dna ◽  
Epstein Barr

Objectives. To explore effects of Epstein-Barr virus (EBV) infection on CD19+ B lymphocytes in patients with immunorelated pancytopenia (IRP). Methods. An enzyme-linked immunosorbent assay (ELISA) in vitro diagnostic kit was used to detect EBV capsid antigen- (CA-) IgG and VCA-IgM antibodies in the serum. We analyzed the EBV-DNA copies of CD19+ B lymphocyte by using real-time quantitative polymerase chain reaction (RT-qPCR). CD21, CD23, CD5, CD80, and CD86 receptors on the surfaces of CD19+ B cells were detected by flow cytometry (FCM). The correlation between these receptors and EBV-DNA copies were evaluated. Results. The results revealed that the positive rate of EBVCA-IgM and CD19+ B lymphocyte EBV-DNA copy in the IRP group were significantly higher than those in the control group (P<0.05). CD19+ B lymphocyte EBV-DNA copies were also more abundant in IRP patients than in control subjects (P<0.05). Expression levels of the CD21, CD23, CD5, CD80, and CD86 receptors on the surfaces of CD19+ B cells in IRP patients with anti-EBVCA IgM positivity were significantly higher than those in anti-EBVCA IgM negativity IRP patients (P<0.05). The results revealed that EBV-DNA copy numbers were positively correlated with CD21, CD23, CD5, CD80, and CD86 expression. Conclusions. EBV infection may activate CD19+ B lymphocytes and further disrupt bone marrow hematopoiesis in IRP patients.

Sign in / Sign up

Export Citation Format

Share Document